Chee Khoon Lee

发表

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

M. Ahn, T. Mok, Yi-long Wu, 2017, The New England journal of medicine.

Can we accurately report PTEN status in advanced colorectal cancer?

T. Price, N. Tebbutt, A. Ruszkiewicz, 2014, BMC Cancer.

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*

R. Simes, T. Price, N. Tebbutt, 2013, Cancer medicine.

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

T. Price, N. Tebbutt, Chee Khoon Lee, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Thomas John, Aleksandra, Aleksandra Markovets, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

V. Gebski, I. Vergote, J. Sehouli, 2015, Gynecologic oncology.

Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.

R. Simes, S. Pearson, Chee Khoon Lee, 2022, Lung cancer.

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.

I. Marschner, T. Mok, J. Yang, 2019, Future oncology.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

M. Reni, J. Tabernero, D. V. Von Hoff, 2020, Pancreas.

Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias

I. Marschner, Chee Khoon Lee, R. Asher, 2020, Acta oncologica.

Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis.

I. Marschner, M. Friedlander, L. Kasherman, 2020, Journal of geriatric oncology.

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis

S. Loi, M. Friedlander, R. Finn, 2018, Breast Cancer Research and Treatment.

A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program

David M. Thomas, M. Cowley, J. Simes, 2021 .

PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.

I. Marschner, J. Yang, W. Cooper, 2022, Future oncology.

When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis

D. Goldstein, Chee Khoon Lee, A. Hadley, 2009, World journal of surgical oncology.

Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.

A. Oza, M. Friedlander, N. Colombo, 2022, Gynecologic oncology.

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.

V. Gebski, M. Friedlander, R. Largillier, 2019, European journal of cancer.

Translating Clinical Trial Evidence to Routine Practice-How Do We Overcome the Barriers?

Chee Khoon Lee, Monica Tang, C. Lee, 2022, JAMA oncology.

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply.

V. Gebski, J. Yang, Chee Khoon Lee, 2018, JAMA oncology.

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.

S. Novello, Chee Khoon Lee, H. Mann, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

Jie Yang, N. Pavlakis, Y. Yatabe, 2022, Clinical lung cancer.

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.

T. Mok, Yi-long Wu, K. Goto, 2021, Lung cancer.

When do patient reported quality of life indicators become prognostic in breast cancer?

J. Bernhard, A. Coates, J. Simes, 2018, Health and Quality of Life Outcomes.

Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).

V. Gebski, J. Simes, D. Cunningham, 2014 .

Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib

T. John, S. Clarke, T. Roberts, 2021, Translational lung cancer research.

M. Stockler, M. King, M. Friedlander, 2013 .

Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting.

V. Gebski, M. Friedlander, S. Lord, 2021, European journal of cancer.

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

C. Scott, P. Francis, M. Friedlander, 2019, British Journal of Cancer.

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer

R. Hettle, Chee Khoon Lee, C. McCrea, 2021, Therapeutic advances in medical oncology.

Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).

M. Reni, J. Tabernero, D. Goldstein, 2017 .

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

V. Gebski, J. Mariadason, J. Simes, 2022, Scientific Reports.

Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

B. Kiely, R. Simes, S. Pearson, 2021, Breast Cancer Research and Treatment.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

V. Gebski, G. Kristensen, P. Witteveen, 2017, Gynecologic oncology.